logo

For the Inventor, By the Inventor

Kobe, Japan

Masanao Shimizu

This inventor holds 11 USPTO granted patents. Top assignee: Dainippon Pharmaceutical Company, Limited. Active years: 1976-1979.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masanao Shimizu. Retrieved from https://idiyas.com/inventor/masanao-shimizu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11

% Patents Active = 100.0

Average Co-Inventor Count = 5.3

ph-index = 7

Forward Citations = 168(Granted Patents)


Location History:

  • Toyonaka, JA (1976 - 1977)
  • Kobe, JA (1976 - 1978)
  • Kobe, JP (1979)

Company Filing History:

goldMedal11 out of 129 
 
Dainippon Pharmaceutical Company, Limited
 patents

Years Active: 1976-1979

Loading Chart...
11 patents (USPTO):Explore Patents
1. 4162316 - 1-Substituted-4-(1,2-diphenylethyl)piperazine derivatives and (1979-07-24),
2. 4080453 - 1-Substituted-4-(1,2-diphenylethyl)piperazine derivatives and (1978-03-21),
3. 4029780 - 3-Piperazinyl 1,2,4-benzothiadiazine 1,1-dioxide derivatives their (1977-06-14),
4. 4017622 - Piperazine derivatives (1977-04-12),
5. 3988456 - 1,2-Diphenylethanolamine derivatives and their salts and the preparation (1976-10-26),
6. 3985875 - .omega.-(N-acylamino)alkylphosphoryl ethanolamines, pharmaceutical (1976-10-12),
7. 3983239 - Hexahydro-.gamma.-carboline derivatives and their salts (1976-09-28),
8. 3981999 - Fish disease treatment (1976-09-21),
9. 3962443 - Antibacterial pharmaceutical compositions and processes for preparation (1976-06-08),
10. 3957788 - 1-Substituted-4-(1,2-diphenylethyl)piperazine derivatives and their (1976-05-18),
11. 3948928 - 3-Substituted-1,2-benzisoxazoles and pharmaceutically acceptable acid (1976-04-06),

Title: The Innovative Mind of Masanao Shimizu

Introduction

Masanao Shimizu is a prominent inventor based in Kobe, Japan, known for his significant contributions to the field of pharmaceutical chemistry. With a portfolio of 11 patents, his work emphasizes innovation and the development of novel compounds that have potential therapeutic applications.

Latest Patents

Shimizu's latest patents include groundbreaking developments in piperazine derivatives. His inventions encompass 1-Substituted-4-(1,2-diphenylethyl)piperazine derivatives, characterized by unique structural formulas involving various substituents such as hydroxy, methoxy, and alkoxy groups. These compounds are designed to produce analgesic or antitussive compositions with essential active ingredients. His meticulous formulations open new avenues for pharmaceutical applications, highlighting his commitment to advancing healthcare solutions.

Career Highlights

Masanao Shimizu works at Dainippon Pharmaceutical Company, Limited, where he has thrived in a dynamic environment, fostering innovation and collaboration. His expertise in medicinal chemistry has led to numerous advancements in drug discovery and development, earning him recognition in the scientific community.

Collaborations

Throughout his career, Shimizu has collaborated with various talented individuals, including Haruki Nishimura and Hitoshi Uno. These partnerships have been pivotal in enhancing research efforts and driving the success of their innovative projects. Together, they have contributed to the creation of impactful pharmaceutical products, showcasing the power of teamwork in the field of innovation.

Conclusion

Masanao Shimizu's inventive spirit and dedication to pharmaceutical research exemplify the essence of innovation in science. His patents not only illustrate his commitment to advancing medicine but also reflect the collaborative efforts that drive successful discoveries. As he continues to explore new frontiers, the impact of his work promises to enrich the field of healthcare significantly.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…